Research map: Treatment of adult acute lymphoblastic leukemia—a therapeutic revolution in the making

Back to the article

Papers in this map

  1. Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome–positive ALL · Philippe H. Rousselot · 2016 · 330 citations · Cited by this paper
  2. Five-year follow-up of OPTIC: long-term efficacy, safety, and mutation analyses of ponatinib in chronic-phase chronic myeloid leukemia from a randomized phase 2 trial · Hagop M. Kantarjian · 2026 · 1 citation · Related
  3. A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy · David M. Cordas dos Santos · 2024 · 287 citations · Cited by this paper
  4. Olverembatinib plus immunotherapy versus olverembatinib plus allogeneic hematopoietic cell transplantation in adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia · Chenying Li · 2026 · 1 citation · Related
  5. Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults · Mark Robert Litzow · 2024 · 272 citations · Cited by this paper
  6. Long-term follow-up of the transplant-eligible cohort of the EMN12/HOVON-129 study for primary plasma cell leukemia patients · 2026 · Related
  7. A population-based cytogenetic study of adults with acute lymphoblastic leukemia · Anthony V. Moorman · 2009 · 247 citations · Cited by this paper
  8. Prospective phase II study of frontline Helicobacter pylori eradication therapy for early-stage extragastric mucosa-associated lymphoid tissue lymphoma · 2026 · Related
  9. Obecabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic Leukemia · Claire Roddie · 2024 · 239 citations · Cited by this paper
  10. Fixed-dose inotuzumab ozogamicin (INO) combined with Vincristine and Prednisone (VP) regimen as induction therapy for newly diagnosed B-cell acute lymphocytic leukemia (B-ALL): a multi-center, open-label, single-arm, prospective clinical study · 2026 · Related
  11. Safety and Efficacy of Blinatumomab in Combination With a Tyrosine Kinase Inhibitor for the Treatment of Relapsed Philadelphia Chromosome-positive Leukemia · Rita Elias Assi · 2017 · 165 citations · Cited by this paper
  12. Linvoseltamab outcomes by frailty status in patients with relapsed/refractory multiple myeloma: a subgroup analysis of the LINKER-MM1 study · 2026 · Related
  13. Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trial · Elias Joseph Jabbour · 2023 · 118 citations · Cited by this paper
  14. Response profile and long-term outcomes in Cyclin D1-overexpressing multiple myeloma: insights from the CASSIOPEIA trial · 2026 · Related
  15. Overall survival among older US adults with ALL remains low despite modest improvement since 1980: SEER analysis · Mark Blaine Geyer · 2017 · 117 citations · Cited by this paper
  16. Preclinical and clinical efficacy of the HDAC6 inhibitor ricolinostat in combination with BCR pathway inhibitors in relapsed/refractory chronic lymphocytic leukemia · 2026 · Related
  17. Frontline combination of ponatinib and hyper‐CVAD in Philadelphia chromosome‐positive acute lymphoblastic leukemia: 80‐months follow‐up results · Hagop M. Kantarjian · 2023 · 105 citations · Cited by this paper
  18. Venetoclax, azacitidine, and G-CSF targeting molecular residual disease in CBFB::MYH11 AML resistant to high-dose cytarabine · 2026 · Related
  19. Treatment of Adults With Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia—From Intensive Chemotherapy Combinations to Chemotherapy-Free Regimens · Elias Joseph Jabbour · 2022 · 104 citations · Cited by this paper
  20. Long-term follow-up of blinatumomab in patients with relapsed/refractory Philadelphia chromosome–positive B-cell precursor acute lymphoblastic leukaemia: Final analysis of ALCANTARA study · Giovanni Martinelli · 2021 · 98 citations · Cited by this paper
  21. Results of the Simultaneous Combination of Ponatinib and Blinatumomab in Philadelphia Chromosome-Positive ALL · Hagop M. Kantarjian · 2024 · 89 citations · Cited by this paper
  22. Inotuzumab Ozogamicin as Induction Therapy for Patients Older Than 55 Years With Philadelphia Chromosome–Negative B-Precursor ALL · Matthias Stelljes · 2023 · 88 citations · Cited by this paper
  23. Blinatumomab compared with standard of care for the treatment of adult patients with relapsed/refractory Philadelphia chromosome–positive B‐precursor acute lymphoblastic leukemia · Alessandro Rambaldi · 2019 · 76 citations · Cited by this paper
  24. Adult Acute Lymphoblastic Leukemia: 2025 Update on Diagnosis, Therapy, and Monitoring · Hagop M. Kantarjian · 2025 · 61 citations · Cited by this paper
  25. Inotuzumab Ozogamicin and Low-Intensity Chemotherapy in Older Patients With Newly Diagnosed CD22 + Philadelphia Chromosome–Negative B-Cell Precursor Acute Lymphoblastic Leukemia · Patrice Chevallier · 2024 · 46 citations · Cited by this paper
  26. Dose Reduced Chemotherapy in Sequence with Blinatumomab for Newly Diagnosed Older Patients with Ph/BCR::ABL Negative B-Precursor Adult Lymphoblastic Leukemia (ALL): Preliminary Results of the GMALL Bold Trial · Nicola Goekbuget · 2023 · 39 citations · Cited by this paper
  27. Acute lymphocytic leukaemia · Hagop Kantarjian · 2025 · 37 citations · Cited by this paper
  28. Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib · Elias Joseph Jabbour · 2024 · 32 citations · Cited by this paper
  29. Sequential Chemotherapy and Blinatumomab to Improve Minimal Residual Disease in Adult Ph- B-Lineage Acute Lymphoblastic Leukemia. Final Results of the Phase II Gimema LAL2317 Trial · Sabina Chiaretti · 2023 · 29 citations · Cited by this paper
  30. Hyper‐ CVAD and Sequential Blinatumomab Without and With Inotuzumab in Young Adults With Newly Diagnosed Philadelphia Chromosome‐Negative B‐Cell Acute Lymphoblastic Leukemia · Hagop M. Kantarjian · 2025 · 28 citations · Cited by this paper
  31. Using immunotherapy and novel trial designs to optimise front-line therapy in adult acute lymphoblastic leukaemia: breaking with the traditions of the past · Nicholas James Short · 2023 · 26 citations · Cited by this paper
  32. Molecular characterization and predictors of relapse in patients with Ph + ALL after frontline ponatinib and blinatumomab · Nicholas James Short · 2025 · 25 citations · Cited by this paper
  33. Management of Adult Acute Lymphoblastic Leukemia · Hagop M. Kantarjian · 2025 · 24 citations · Cited by this paper
  34. Treatment‐free remission in nontransplanted patients with Philadelphia chromosome‐positive acute lymphoblastic leukemia · Eitan Kugler · 2025 · 18 citations · Cited by this paper
  35. First results of the Phase III GIMEMA ALL2820 trial comparing ponatinib plus blinatumomab to imatinib and chemotherapy for newly diagnosed adult ph+ acute lymphoblastic leukemia patients · Sabina Chiaretti · 2025 · 14 citations · Cited by this paper
  36. Inotuzumab Ozogamicin Then Blinatumomab for Older Adults With Newly Diagnosed B-Cell ALL: Alliance Study A041703 Cohort 1 Results · Matthew Joseph Wieduwilt · 2025 · 11 citations · Cited by this paper
  37. Olverembatinib in chronic myeloid leukemia—Review of historical development, current status, and future research · Hagop M. Kantarjian · 2025 · 9 citations · Cited by this paper
  38. The evolving therapeutic revolution in adult acute lymphoblastic leukemia · Hagop M. Kantarjian · 2025 · 9 citations · Cited by this paper
  39. Olverembatinib combined with venetoclax and reduced-intensity chemotherapy for adult newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia: a single-center, single-arm, phase 2 trial · Xiaoyuan Gong · 2025 · 9 citations · Cited by this paper

Source: OpenAlex (CC0)